Compare MTG & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTG | RGEN |
|---|---|---|
| Founded | 1957 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.6B |
| IPO Year | 2008 | 1995 |
| Metric | MTG | RGEN |
|---|---|---|
| Price | $31.22 | $167.57 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $28.50 | ★ $167.67 |
| AVG Volume (30 Days) | ★ 1.4M | 936.5K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | 8.65 | ★ 286.96 |
| EPS | ★ 1.62 | 0.24 |
| Revenue | ★ $1,213,636,000.00 | $141,236,000.00 |
| Revenue This Year | $2.50 | $14.30 |
| Revenue Next Year | $1.77 | $14.52 |
| P/E Ratio | ★ $19.47 | $701.96 |
| Revenue Growth | 0.49 | ★ 35.10 |
| 52 Week Low | $24.69 | $100.99 |
| 52 Week High | $31.89 | $188.73 |
| Indicator | MTG | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 65.79 | 51.33 |
| Support Level | $25.57 | $156.65 |
| Resistance Level | $31.62 | $173.10 |
| Average True Range (ATR) | 0.38 | 7.57 |
| MACD | -0.07 | -1.91 |
| Stochastic Oscillator | 97.38 | 15.97 |
MGIC Investment Corp provides private mortgage insurance, other mortgage credit risk management solutions, and ancillary services. The insurance premiums that these customers pay for the protection account for close to the majority of the company's total revenue. Investment income accounts for the remaining revenue. The company sells its insurance products in all states of the United States and in Puerto Rico. Its greatest exposure is in California, Florida, Texas, Pennsylvania, Ohio, Illinois, Virginia, North Carolina, Georgia, and New York.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.